Вход Регистрация
Контакты Новости сайта Карта сайта Новости сайта в формате RSS
 
 
Новости для выпускников
МГУ им.Ломоносова
SUBSCRIBE.RU
 
База данных выпускников
 
 
Рассылки Subscribe.ru
Выпускники МГУ
Выпускники ВМиК
Долголетие и омоложение
Дайв-Клуб МГУ
Гольф
Новости психологии
 
Рассылки Maillist.ru
Выпускники МГУ
Активное долголетие, омоложение организма, геропротекторы
 

Внутримышечные инъекции - главная надежда на излечение от болезни Альцгеймера. MPL (monophosphoryl lipid A)

Сотрудники Университета Лаваль, Университетского госпиталя Квебека и компании GlaxoSmithKline заявляют: им удалось подойти вплотную к получению вакцины против болезни Альцгеймера, пишетThe Best medical cover.

Ученые выделили молекулу MPL, на которую они, как раз, делают основную ставку. Тесты, проводившиеся на грызунах, показали: еженедельные инъекции молекулы MPL в течение 12 недель позволяли убрать до 80% опасных для мозга бляшек. Именно из-за этих аномальных отложений развиваются симптомы болезни.

Дополнительные тесты, оценивающие способность мышей к обучению, также продемонстрировали значительное улучшение когнитивных функций за отведенное время. На практике молекулу можно вводить в форме внутримышечной инъекцией уже болеющим людям. Это позволит замедлить развитие недуга. 

Правда, подобные инъекции, возможно, станут и действенной превентивной терапией. Над вакциной эксперты начали работать еще десять лет назад. И, наконец, совершился прорыв, комментирует доктор Серж Ривест.

 

Vaccine for Alzheimer's may be on the horizon

January 16, 2013

Researchers are on the tipping point of discovering a vaccine for Alzheimer's

A breakthrough Canadian study has indicated there may be a vaccine against the threat of Alzheimer's on the horizon for those most at risk for the disease.

Research from Laval University, the University Hospital of Quebec and GlaxoSmithKline has identified a molecule, MPL, that may defend against cognitive decline.

In a test carried out on mice, it was shown that weekly injections of MPL over a 12-week period eliminated up to 80 percent of senile plaques - abnormal structures in the brains of Alzheimer's disease patients.

As the study observed, additional tests measuring the mice's ability to learn also showed significant improvement in their cognitive function over the same period.

On the one hand, MPL could be administered as an intramuscular injection to people with Alzheimer's to slow the progression of the disease. However, it could also be used as a preventative in those with risk factors for the illness.

Dr Serge Rivest commented: "When our team started working on Alzheimer's disease a decade ago, our goal was to develop better treatment for Alzheimer's patients.

"With the discovery announced today, I think we're close to our objective."

Major Step Toward an Alzheimer's Vaccine

Jan. 15, 2013 - A team of researchers from Université Laval, CHU de Québec, and pharmaceutical firm GlaxoSmithKline (GSK) has discovered a way to stimulate the brain's natural defense mechanisms in people with Alzheimer's disease. This major breakthrough, details of which are presented January 15 in an early online edition of the  Proceedings of the National Academy of Sciences  ( PNAS ), opens the door to the development of a treatment for Alzheimer's disease and a vaccine to prevent the illness.

 

One of the main characteristics of Alzheimer's disease is the production in the brain of a toxic molecule known as amyloid beta. Microglial cells, the nervous system's defenders, are unable to eliminate this substance, which forms deposits called senile plaques.

The team led by Dr. Serge Rivest, professor at Université Laval's Faculty of Medicine and researcher at the CHU de Québec research center, identified a molecule that stimulates the activity of the brain's immune cells. The molecule, known as MPL (monophosphoryl lipid A), has been used extensively as a vaccine adjuvant by GSK for many years, and its safety is well established.

In mice with Alzheimer's symptoms, weekly injections of MPL over a twelve-week period eliminated up to 80% of senile plaques. In addition, tests measuring the mice's ability to learn new tasks showed significant improvement in cognitive function over the same period.

The researchers see two potential uses for MPL. It could be administered by intramuscular injection to people with Alzheimer's disease to slow the progression of the illness. It could also be incorporated into a vaccine designed to stimulate the production of antibodies against amyloid beta. "The vaccine could be given to people who already have the disease to stimulate their natural immunity," said Serge Rivest. "It could also be administered as a preventive measure to people with risk factors for Alzheimer's disease."

"When our team started working on Alzheimer's disease a decade ago, our goal was to develop better treatment for Alzheimer's patients," explained Professor Rivest. "With the discovery announced today, I think we're close to our objective."

  • MonosphosphoryL Lipid A (MPL-A) from Salmonella minnesota, R595 (Re)

Description: MonosphosphoryL Lipid A (MPL-A) from Salmonella minnesota, R595 (Re)

Humans as well as other vertebrates are often exposed to lipopolysaccharide (LPS), for instance via enterobacteria. LPS responses are mediated via Toll-like receptor 4 (TLR4). TLRs are conserved pattern recognition receptors which recognize and respond to molecules derived from bacterial, viral and fungal pathogens, such as LPS from the outer membrane of Gram negative bacteria. Recognition of LPS occurs largely by the TLR4/MD2/CD14 complex, expressed among others by macrophages and dendritic cells. The acute phase LPS-binding protein (LBP) recognizes the lipid A part of LPS and catalyses the monomeric LPS transfer to CD14. This facilitates the LPS transfer to TLR4/MD2. All immunological activity of LPS is exclusively dependent upon the presence of TLR4 as determined by the usage of the corresponding control cells, where TLR4 is missing. Recognition of LPS triggers a cascade of adverse systemic responses and organ failure (septic shock).
LPS is a key component of the cell wall of gram negative bacteria (S-form LPS). The molecule consist of three structural regions: the O-polysaccharide chain made up of repeating oligosaccharide units, the core oligosaccharide and- Lipid A. The latter is responsible for the endotoxic activity of the entire molecule. R-form LPS synthesized by the so-called rough (R) mutants of gram-negative bacteria lacks the O-specific chain. Furthermore, the core-oligosaccharide may be present in different degrees of completion, depending on the class (Ra to Re) to which the mutant belongs. LPS from wild type bacteria are always a highly heterogeneous mixtures of S-form LPS molecules containing 1 to over 50 repeating oligosaccharide units and contain a varying proportion of R-form molecules. R-form LPS and lipid A, but not S-form LPS, are capable of inducing TNF-; responses also in the absence of CD14. S- and R-form LPS show marked differences in the kinetics of their blood clearance and cellular uptake as well as in the ability to induce oxidative burst in human granulocytes and to activate the host complement system.
In mice, defects in TLR4 result in LPS unresponsiveness. According to current consensus, activation of TLR4 is preceded by the transfer of LPS to membrane-bound or soluble CD14 by LPS-binding protein (LBP). This mechanism is believed to be true for LPS signaling in general.
Re-form LPS and lipid A, but not S-form LPS, are capable of inducing TNF-a responses also in the absence of CD14.
LPS is an amphipathic molecule whose hydrophobicity decreases when the length of the sugar part of LPS increases. S- and R-form LPS show marked differences in the kinetics of their blood clearance and cellular uptake as well as in the ability to induce oxidative burst in human granulocytes and to activate the host complement system. MPL-A is a detoxified derivative of Lipid A that is the active endotoxic component of LPS. MPL-A represents an important adjuvant in vaccines.

Specifications

Catalog number HC4058
Product type LPS ligands
Quantity 0.5 mg
Formulation 0.5 mg (1 mg/ml) ready-to-use in aqueous solution in ultra-pure, endotoxin-free, sterile, double-distilled water.
Application Functional studies
Use Do not pre-dilute in buffer (e.g) PBS as this will lead to precipitation of MPLA.
Prepare diluted MPLA working solutions just prior to use, keep sterile. Ready-made solution is cell culture-grade.
Optimal concentration is dependent upon cell type, species, desired activation and analysis: 0.1 -1.0 µg/ml.
Does not activate any TLR other than TLR4 as tested in relevant biological systems.
Storage and Stability Product should be stored at 4 °C. Do not freeze. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. Use of this product for human or animal testing is extremely hazardous and may result in disease, severe injury, or death.
It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Material Safety Data Sheet: This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, inhale or get in the blood stream.
Как помочь проекту "Активное долголетие"


  Рекомендовать »   Написать редактору  
  Распечатать »
 
  Дата публикации: 29.09.2012  
 

     Дизайн и поддержка: Interface Ltd.

    
Rambler's Top100